Akari Therapeutics Plc(AKTX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Akari Therapeutics Plc (AKTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AKTX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.6m in revenue and is scored on the micro-cap board instead. Top institutional holders of AKTX by reported 13-F value include MMCAP International SPC, Cresset Asset Management, JANE STREET GROUP, based on the most recent SEC filings. AKTX trades on the Nasdaq exchange and files with the SEC under CIK 1541157. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Akari Therapeutics Plc directly from SEC EDGAR.

Net Income

$-4.8M

AKTX key financials by period

Akari Therapeutics Plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202310-K$367.9K$-10.0M—
FY 202210-K$607.7K$-17.7M—

Institutions holding AKTX

Institutional investors reporting a position in Akari Therapeutics Plc on SEC Form 13F.
InstitutionSharesValueReported
MMCAP International SPC100,000$1.0M2026-06-30
Cresset Asset Management20,561$210.6K2026-06-30
JANE STREET GROUP15,463$158.4K2026-06-30
HRT FINANCIAL13,745$140.0K2026-06-30
CITADEL ADVISORS10,000$102.5K2026-06-30
IFP Advisors181$1.9K2026-06-30
SBI Securities , Ltd.14$143.002026-06-30
Caitong International Asset Management , Ltd8$82.002026-06-30
NORTHWESTERN MUTUAL WEALTH MANAGEMENT7$72.002026-06-30
Truvestments Capital1$10.002026-06-30
SEC EDGAR: CIK 1541157 →
AKTX

Akari Therapeutics Plc

AKTX
NasdaqMega CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.6M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-4.81M

EPS (Diluted)

Q2 2026
EDGAR

$0.00

Top Institutional Holders

as of Q2 2026
$1.64M total
MMCAP International Inc. SPC
$1.02MNew
Cresset Asset Management, LLC
$210.6K0.0%
JANE STREET GROUP, LLC
$158.4KNew
HRT FINANCIAL LP
$140.0KNew
CITADEL ADVISORS LLC
$102.5KNew
IFP Advisors, Inc
$1.9K0.0%
SBI Securities Co., Ltd.
$143+180.0%
Caitong International Asset Management Co., Ltd
$82New
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$72New
Truvestments Capital LLC
$100.0%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…